RecruitingPhase 1

Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

United States18 participantsStarted 2025-12-18

Plain-language summary

This is a multi-center, open label, Phase 1b study of NXP900 in combination with osimertinib in subjects with advanced, progressing, EGFR-mutated non-small cell lung cancer (NSCLC)

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Provide written informed consent.
✓. 18 years old or older.
✓. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
✓. Unresectable, metastatic or locally advanced EGFR-mutated NSCLC.
✓. Prior treatment with osimertinib as first or second line, as single agent or in combination with chemotherapy, in the metastatic or locally advanced setting.

Exclusion criteria

✕. Subject's cancer has a known oncogenic driver alteration other than EGFR.
✕. Known EGFR mutations that cause resistance to osimertinib
✕. Known human epidermal growth factor receptor 2 (HER2) overexpression
✕. Any contraindications to treatment with osimertinib

What they're measuring

Number of patients with treatment related adverse events and/or clinical laboratory abnormalities

Timeframe: Up to 30 days post treatment

Objective response rate (ORR)

Timeframe: Up to approximately 12 months

Duration of Response (DoR)

Timeframe: Up to approximately 12 months

Disease Control Rate (DCR)

Timeframe: Up to approximately 12 months

Trial details

NCT IDNCT07315113

SponsorNuvectis Pharma, Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-12

Contact for this trial

Erin Belshaw

12016278129 ebelshaw@nuvectis.com

View on ClinicalTrials.gov More EGFR Mutation Positive Non-small Cell Lung Cancer trials